EMNPD

NPs Basic Information
NPs Species Source
NPs Content
NPs Biological Activity
NPs Physi-Chem Properties
NPs ADMET Properties
Similar NPs and Drugs

NPs Basic Information

Download MOL File	Name	Rosmarinic acid
	Molecular Formula	C18H16O8
	IUPAC Name*	(2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxypropanoic acid
	SMILES	C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)O)O
	InChI	InChI=1S/C18H16O8/c19-12-4-1-10(7-14(12)21)3-6-17(23)26-16(18(24)25)9-11-2-5-13(20)15(22)8-11/h1-8,16,19-22H,9H2,(H,24,25)/b6-3+/t16-/m1/s1
	InChIKey	DOUMFZQKYFQNTF-WUTVXBCWSA-N
	Synonyms	rosmarinic acid; 20283-92-5; Rosemary acid; Rosmarinicacid; (R)-rosmarinic acid; Labiatic acid; Labiatenic acid; trans-Rosmarinic acid; Rosmarinate; Rosmarinic acid racemate; Rosmarinic-acid; 537-15-5; (R,E)-3-(3,4-dihydroxyphenyl)-2-((3-(3,4-dihydroxyphenyl)acryloyl)oxy)propanoic acid; MQE6XG29YI; (2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxypropanoic acid; CHEMBL324842; CHEBI:50371; (R)-O-(3,4-Dihydroxycinnamoyl)-3-(3,4- dihydroxyphenyl)lactic acid; (2R)-3-(3,4-dihydroxyphenyl)-2-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]propanoic acid; (2r)-3-(3,4-Dihydroxyphenyl)-2-{[(2e)-3-(3,4-Dihydroxyphenyl)prop-2-Enoyl]oxy}propanoic Acid; Rosemaric acid; (R)-O-(3,4-Dihydroxycinnamoyl)-3-(3,4-dihydroxyphenyl)lactic acid; (2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-propanoic acid; CINNAMIC ACID, 3,4-DIHYDROXY-, 2-ESTER with 3-(3,4-DIHYDROXYPHENYL)LACTIC ACID; 3,4-Dihydroxycinnamic acid (R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethyl ester; Benzenepropanoic acid, alpha-((3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-3,4-dihydroxy-; UNII-MQE6XG29YI; Rosmarimic acid; CCRIS 9361; RM 21A; HSDB 7688; NPLC 0542; R-(+)-2-(3,4-Dihydroxycinnamoyloxy)-3-(3,4-dihydroxyphenyl)propionic acid; BENZENEPROPANOIC ACID, .ALPHA.-(((2E)-3-(3,4-DIHYDROXYPHENYL)-1-OXO-2-PROPENYL)OXY)-3,4-DIHYDROXY-, (.ALPHA.R)-; Benzenepropanoic acid, .alpha.-[[(2E)-3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-3,4-dihydroxy-, (.alpha.R)-; MFCD00017740; Rosmarinic acid, 2; ORISTRACT ROA; Rosmarinic acid, 96%; bmse000648; ROSMARINIC ACID [MI]; MLS000697677; ROSMARINIC ACID [HSDB]; ROSMARINIC ACID [INCI]; MEGxp0_000163; RM-21A; SCHEMBL1650675; SCHEMBL2028694; ACon1_001068; CHEBI:92370; cid_5281792; NPLC-0542; DTXSID20896987; ROSMARINIC ACID [USP-RS]; HMS2227A13; HMS3266D13; HMS3411K16; HMS3649C22; HMS3675K16; HMS3885I15; ZINC899870; HY-N0529; BDBM50133496; s3612; ZB1872; 3,4-Dihydroxycinnamic acid 2-ester with 3-(3,4-dihydroxyphenyl)lactic acid; AKOS015892734; CCG-207919; CCG-208268; NCGC00169708-01; AC-33965; AS-35341; Benzenepropanoic acid,a-[[(2E)-3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-3,4-dihydroxy-,(aR)-; SMR000445579; C01850; EN300-364852; 225R532; A814378; SR-01000946599; Q-100246; SR-01000946599-1; (2R)-O-caffeoyl-3-(3,4-dihydroxyphenyl)lactic acid; Q50380051; F0001-0715; ROSMARINIC ACID (CONSTITUENT OF ROSEMARY) [DSC]; 93B6A3BF-927D-4C59-8A49-29BDBC87C194; Rosmarinic acid, primary pharmaceutical reference standard; ROSMARINIC ACID (CONSTITUENT OF HOLY BASIL LEAF) [DSC]; Rosmarinic acid, European Pharmacopoeia (EP) Reference Standard; Rosmarinic acid, >=98% (HPLC), from Rosemarinus officinalis L.; Rosmarinic acid, United States Pharmacopeia (USP) Reference Standard; (2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxypropanoicacid; (R)-2-[3-(3,4-Dihydroxyphenyl)acryloyloxy]-3-(3,4-dihydroxyphenyl)propionic acid; (R,E)-3-(3,4-dihydroxyphenyl)-2-((3-(3,4-dihydroxyphenyl)acryloyl)oxy)propanoicacid; (R,E)-3-(3,4-dihydroxyphenyl)-2-(3-(3,4-dihydroxyphenyl)acryloyloxy)propanoic acid; 3-(3,4-DIHYDROXYPHENYL)ACRYLIC ACID-1-CARBOXY-2-(3,4-DIHYDROXYPHENYL)ETHYL ESTER; alpha-(((3,4-Dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-3,4-dihydroxybenzenepropanoic acid; (2R)-3-(3,4-DIHYDROXYPHENYL)-2-{[3-(3,4-DIHYDROXYPHENYL)PROP-2-ENOYL]OXY}PROPANOIC ACID; [R-(+)]-?-[[3-(3,4-Dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-3,4-dihydroxybenzenepropanoic acid; 162281-84-7; BENZENEPROPANOIC ACID, .ALPHA.-(((2E)-3-(3,4-DIHYDROXYPHENYL)-1-OXO-2-PROPEN-1-YL)OXY)-3,4-DIHYDROXY-, (.ALPHA.R)-; Benzenepropanoic acid, .alpha.-((3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-3,4-dihydroxy-, (R-(E))-; Benzenepropanoic acid, alpha-((3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-3,4-dihydroxy-, (R-(E))-
	CAS	20283-92-5
	PubChem CID	5281792
	ChEMBL ID	CHEMBL324842

*Note: the IUPAC Name was collected from PubChem.

Chemical Classification:	Kingdom: Organic compounds Superclass: Phenylpropanoids and poly Class: Cinnamic acids and deriva Subclass: Hydroxycinnamic acids and Direct Parent: Coumaric acids and deriva	ClassyFire Version 1.0 PMID:27867422

NPs Species Source

	Endophyte ID	Endophyte Name	Family	Genus	Taxonomy ID	GenBank ID	Closest GenBank ID	Reference
	Endophyte ID	Endophyte Name	Family	Genus	Taxonomy ID	GenBank ID	Closest GenBank ID	Reference

NPs Content

*Note: The vaules in Content Percentage are calculated by dividing the content value by the maximum content value in NP Content.

**Note: The units with different NP content, due to their incomparable values, are separated into different tables.

NPs Biological Activity

	Bioactivity Name	Target ID	Target Name	Target Type	Target Organism	Target Organism ID	Potency of Bioactivity	Activity Type	Value	Unit	Endophyte ID	Endophyte Name
	Bioactivity Name	Target ID	Target Name	Target Type	Target Organism	Target Organism ID	Potency of Bioactivity	Activity Type	Value	Unit	Endophyte ID	Endophyte Name

NPs Physi-Chem Properties

Molecular Weight:	360.3	ALogp:	2.4
HBD:	5	HBA:	8
Rotatable Bonds:	7	Lipinski's rule of five:	Accepted
Polar Surface Area:	145.0	Aromatic Rings:	2
Heavy Atoms:	26	QED Weighted:	0.3

NPs ADMET Properties*

ADMET: Absorption

Caco-2 Permeability:	-6.005	MDCK Permeability:	0.00000694
Pgp-inhibitor:	0	Pgp-substrate:	0.004
Human Intestinal Absorption (HIA):	0.231	20% Bioavailability (F20%):	0.505
30% Bioavailability (F30%):	0.994

ADMET: Distribution

Blood-Brain-Barrier Penetration (BBB):	0.049	Plasma Protein Binding (PPB):	97.72%
Volume Distribution (VD):	0.369	Fu:	2.04%

ADMET: Metabolism

CYP1A2-inhibitor:	0.138	CYP1A2-substrate:	0.043
CYP2C19-inhibitor:	0.117	CYP2C19-substrate:	0.041
CYP2C9-inhibitor:	0.554	CYP2C9-substrate:	0.798
CYP2D6-inhibitor:	0.06	CYP2D6-substrate:	0.204
CYP3A4-inhibitor:	0.092	CYP3A4-substrate:	0.041

ADMET: Excretion

Clearance (CL):

15.347

Half-life (T1/2):

0.959

ADMET: Toxicity

hERG Blockers:	0.015	Human Hepatotoxicity (H-HT):	0.446
Drug-inuced Liver Injury (DILI):	0.367	AMES Toxicity:	0.035
Rat Oral Acute Toxicity:	0.451	Maximum Recommended Daily Dose:	0.035
Skin Sensitization:	0.951	Carcinogencity:	0.275
Eye Corrosion:	0.005	Eye Irritation:	0.852
Respiratory Toxicity:	0.052

*Note: the ADMET properties was calculated by ADMETlab 2.0. Reference: PMID: 33893803.

Similar Compounds*

Compounds similar to EMNPD with top10 similarity:

Similar NPs					Similar Drugs
NPs ID	NPs 2D Structure	Similarity Score			TTD ID	Drug 2D Structure	Similarity Score
ENC002584		0.456			D0U3YB		0.489
ENC001848		0.433			D0KN2M		0.483
ENC001440		0.432			D0V9EN		0.432
ENC001416		0.419			D08HVR		0.403
ENC002823		0.409			D00KRE		0.365
ENC001543		0.408			D0U0OT		0.354
ENC001471		0.408			D0BA6T		0.325
ENC001917		0.408			D02FCQ		0.321
ENC000127		0.403			D0J7RK		0.317
ENC002582		0.395			D04AIT		0.316

*Note: the compound similarity was calculated by RDKIT.